Cocrystal pharma's participation in the noble capital markets c-suite interview series is now available online

Bothell, wash., june 09, 2021 (globe newswire) -- cocrystal pharma, inc. (nasdaq: cocp), (“cocrystal” or the “company”), a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, the sars-cov-2 virus, hepatitis c viruses and noroviruses, announces that management's participation in the noble capital markets c-suite interview series is now available online. during the 30-minute video int e rview hosted by noble capital markets senior equity research analyst robert leboyer, cocrystal discussed its antiviral drug-discovery and development work and provided program updates.
COCP Ratings Summary
COCP Quant Ranking